Source the Telegraph: “As doctors, we are left feeling powerless when we deliver the devastating diagnosis of PPMS to people 
because we know there is currently no disease-modifying treatment available to help them.
“It is even more frustrating that an effective treatment that can help slow the disease has been developed and made available across the globe yet people in England and Wales will continue to suffer disability worsening because of an archaic and inflexible medicine assessment system.”
Thousands of multiple sclerosis patients have been denied a drug which could delay them needing a wheelchair for seven years, even though the manufacturer has agreed to slash the price.
The National Institute for Health and Care Excellence (Nice) today announced that it will not be funding ocrelizumab for primary progressive MS available on the NHS in England and Wales. Read on.